FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
OC-09 | Atogepant in treatment-refractory chronic migraine: is a revision of current criteria for refractory migraine appropriate? Lorenzo Tartaglione, Marcello Silvestro, Ilaria Orologio, Marcella Marziani, Francesco Maurizio Chianese, Pasquale Sozio, Alessandro Tessitore, Gioacchino Tedeschi, Antonio Russo | Headache Center, Department of Advanced Medical and Surgical Sciences (DAMSS), University of Campania "Luigi Vanvitelli", Naples, Italy
273 -
PO-16 | Neurophysiological effects of atogepant in high-frequency episodic migraine B. Agostini,1,2 F. Cammarota,1,2 R. De Icco,1,2 V. Grillo,1,2 G. Vaghi,1,2 F. Bighiani1,2, M. Corrado,2 A. Antoniazzi,1,2 M. Giraudo,1,2 A. Solfrizzi,1,2 R. Greco,2 C. Demartini,1,2 A. Zanaboni,1,2 M. Francavilla,1,2 S. Facchetti,1,2 G. Sances,2 C. Tassorelli1,2 | 1Department of Brain and Behavioral Sciences, University of Pavia; 2Headache Science and Neurorehabilitation Unit, IRCCS Mondino Foundation, Pavia, Italy
190 -
OC-04 | The chronopharmacology of atogepant in migraine prevention: a real-world evaluation of influence of timing of administration on effectiveness and tolerability Luigi Francesco Iannone,1,2 Gabriele Sebastianelli,3 Flavia Lo Castro,2 Federico De Santis,4 Michele Corrado,5 Marilena Marcosano,6,7 Raffaele Ornello,4 Licia Grazzi,8 Danilo Antonio Montisano,8 Francesco De Cesaris,9 Antonio Munafò,9 Gianluca Avino,10 Michele Trimboli,11 Maria Albanese,12 Antonio Russo,13 Giorgio Dalla Volta,14 Marina Romozzi,15 Paola Merlo,16 Luisa Fofi,6,7 Alberto Doretti,17 Gloria Vaghi,5 Francesca Pistoia,4 Delfina Ferrandi,18 Stefania Battistini,19 Gianluca Coppola,3 Simona Sacco,4 Simona Guerzoni,2 Claudia Altamura,6,7 Fabrizio Vernieri,6,7 On behalf of the Italian Headache Registry (RICe) Study Group | 1Department of Biomedical, Metabolic, and Neural Science, University of Modena and Reggio Emilia; 2Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico di Modena; 3Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome Polo Pontino, Latina; 4Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila; 5Department of Brain and Behavioral Sciences, University of Pavia; Headache Science and Neurorehabilitation Unit, IRCCS Mondino Foundation, Pavia; 6Headache Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Roma; 7Neurology Unit, Università Campus Bio-Medico di Roma; 8Neuroalgology Unit and Headache Center, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan; 9Headache center and Clinical Pharmacology, AOU Careggi, Florence; 10SOC Neurologia, Ospedale di Prato; 11Azienda Ospedaliera-universitaria "Renato Dulbecco", Catanzaro; 12Università Roma Tor Vergata, Roma; 13Università della Campania "Luigi Vanvitelli", Napoli; 14U.O Neurologia, Istituto Clinico Città di Brescia, Gruppo San Donato, Brescia; 15Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy; 16UO di Neurologia, Humanitas Gavazzeni, Bergamo; 17Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano; 18Neurology Department, Azienda Ospedaliero Universitaria, Santi Antonio e Biagio e Cesare Arrigo, Alessandria; 19Department of Medical, Surgical and Neurological Sciences, University of Siena, Italy
113 -
PO-13 | HD-EEG Delta connectivity rapidly alters after one month of atogepant in migraine patients Maria Albanese,1,2 Matteo Conti,1 Silvio Bagetta,1 Federico Carparelli,2 Vittoria Carla D’Agostino,2 Fabio Placidi,1,2 Alessandro Stefani,1,2 Nicola Biagio Mercuri,1-3 | 1Department of Systems Medicine, University of Rome Tor Vergata, Rome; 2Neurology Unit, Tor Vergata University Hospital, Rome; 3IRCCS Santa Lucia Foundation, Rome, Italy
213 -
PO-79 | Survey on adherence and tolerability of atogepant used as migraine preventive treatment D.A. Montisano,1 G. Vaghi,2,3 A. Paris,1 R. De Icco,2,3 B. Agostini,2,3 M. Giraudo,2,3 A. Solfrizzi,2,3 C. Tassorelli,2,3 G. Sances,3 L. Grazzi | 1Fondazione IRCCS C.Besta Istituto Neurologico, SSD Headache Center, Milan, Italy; 2University of Pavia, Department of Brain and Behavioral Sciences, Pavia, Italy; 3IRCCS Mondino Foundation, Headache Science & Neurorehabilitation Unit, Pavia, Italy
212 -
PO-69 | Three-month atogepant treatment modulates dopaminergic-related functional connectivity in episodic migraine Davide Fedeli,1 Danilo Antonio Montisano,1 Greta Demichelis,1 Giuseppe Ciullo,1,2 Jean Paul Medina Carrion,1 Maria Grazia Bruzzone,1 Emilio Ciusani,1 Alessandra Erbetta,1 Marina Grisoli,1 Erika Guastafierro,1 Domenico D’Amico,1 Alberto Raggi,1 Anna Nigri,1 Licia Grazzi1 | 1Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; 2University of Parma, Parma, Italy
151 -
OC-05 | Mid-term effectiveness and tolerability of atogepant in the prevention of migraine: a real life, prospective, multicentric study (the STAR study) Fabrizio Vernieri,1 Luigi Francesco Iannone,2,3 Gabriele Sebastianelli,4 Flavia Lo Castro,2, Federico De Santis,5 Michele Corrado,6 Marilena Marcosano,1 Raffaele Ornello,5 Licia Grazzi,7 Danilo Antonio Montisano,7 Francesco De Cesaris,8 Antonio Munafò,8 Gianluca Avino,9 Michele Trimboli,10 Maria Albanese,11 Antonio Russo,12 Giorgio Dalla Volta,13 Marina Romozzi,14 Paola Merlo,15 Maria Pia Prudenzano,16 Maria Rosaria Valente,17 Innocenzo Rainero,18 Giada Giuliani,19 Luisa Fofi,1 Alberto Doretti,20 Gloria Vaghi,6 Francesca Pistoia,5 Delfina Ferrandi,21 Stefania Battistini,22 Simona Sacco,5 Simona Guerzoni,2 Claudia Altamura1 on behalf of the Italian Headache Registry (RICe) Study Group | 1Fondazione Policlinico Campus Bio-Medico, Roma; 2AOU Policlinico di Modena; 3Università di Modena e Reggio Emilia. 4Sapienza University of Rome Polo Pontino, Latina; 5University of L’Aquila; 6University of Pavia, Pavia, Italy and IRCCS Mondino Foundation, Pavia; 7IRCCS Istituto Neurologico Carlo Besta, Milano; 8AOU Careggi, Firenze; 9SOC Neurologia, Ospedale di Prato, Prato; 10Azienda Ospedaliera-universitaria "Renato Dulbecco", Catanzaro; 11Università Roma Tor Vergata, Roma; 12Università della Campania "Luigi Vanvitelli", Napoli; 13U.O Neurologia, Istituto Clinico Città di Brescia, Gruppo San Donato, Brescia; 14Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma; 15UO di Neurologia, Humanitas Gavazzeni, Bergamo; 16Clinica Neurologica "L. Amaducci", Azienda Ospedaliero-Universitaria Consorziale di Bari; 17Dipartimento di Neuroscienze, Azienda Sanitaria Universitaria Integrata di Udine; 18Dipartimento di Neuroscienze, Città della Salute e della Scienza di Torino; 19Centro per la diagnosi e terapia delle cefalee, Policlinico Umberto I, Roma; 20IRCCS Istituto Auxologico Italiano, Milano; 21AOU Alessandria; 22University of Siena, Siena, Italy
208 -
PO-77 | Real-world evidence of Atogepant efficacy in patients unresponsive to anti-CGRP monoclonals Matteo Cortinovis, Marco Bolchini, Paola Zavarise, Giulia Campana, Giorgio Dalla Volta | Headache Center, Istituto Clinico Città di Brescia, Gruppo San Donato, Brescia, Italy
228 -
PO-57 | Early treatment with atogepant improves sleep quality without sleep-related adverse events: a prospective observational study Alberto Boccalini,1 Luigi Francesco Iannone,1,2* Flavia Lo Castro,1 Daria Brovia,1 Marina Romozzi,3,4 Fabrizio Vernieri,5,6 Claudia Altamura,5,6 Simona Guerzoni1 | 1Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico di Modena, Modena, Italy; 2Department of Biomedical, Metabolic, and Neural Science, University of Modena and Reggio Emilia, Modena, Italy; 3Dipartimento Universitario di Neuroscienze, Università Cattolica del Sacro Cuore, Rome, Italy; 4Neurologia, Dipartimento di neuroscienze, Organi di Senso e Torace, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; 5Headache Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy; 6Università Campus Bio-Medico di Roma, Italy
136 -
PO-80 | Real-world effectiveness of atogepant for the preventive treatment of migraine in a cohort of multi -refractory patients: a single center study M. De Luca,1 L. Ferraù,1 A. Cafarchio,2 M.S. Adragna,1 M. Autunno1 | 1Unit of Neurology and Neuromuscular Diseases, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy; 2Department of Medicine and Health Sciences “Vincenzo Tibero” DIMES, University of Molise, Campobasso, Italy
214 -
PO-38 | Impact of atogepant on achieving best possible quality of life among patient global impression of change responders Cristina Tassorelli,1 Pranav Gandhi,2 Molly Duan,2 Karen Carr,2 Kandavadivu Umashankar,2 Jonathan Stokes,2 Grace Forde,3 Tanya Bilchik,4 Martina Martini*, Rashmi Halker Singh5 | 1University of Pavia, Pavia, Italy; 2AbbVie, North Chicago, IL, USA; 3North American Partners in Pain Management, North New Hyde Park, NY, USA; 4Department of Neurology, Yale School of Medicine, New Haven, CT, USA; 5Mayo Clinic, Phoenix, AZ, USA *Abbvie Srl, Rome, Italy.
182 -
PO-76 | Atogepant reduces psychological dependence to acute treatments evaluated with the Leeds dependence questionnaire (LDQ): a prospective observational study Luigi Francesco Iannone,1,2 Marina Romozzi,3,4 Alberto Boccalini,1 Flavia Lo Castro,1 Claudia Altamura,5 Fabrizio Vernieri,5 Simona Guerzoni1 | 1Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico di Modena, Modena, Italy; 2Department of Biomedical, Metabolic, and Neural Science, University of Modena and Reggio Emilia, Modena, Italy; 3Dipartimento Universitario di Neuroscienze, Università Cattolica del Sacro Cuore, Rome, Italy; 4Neurologia, Dipartimento di Neuroscienze, Organi di Senso e Torace, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; 5Headache Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy; 6Università Campus Bio-Medico di Roma, Italy
227 -
PO-91 | Real-world evidence of CGRP dual blockade: clinical and biomarker insights from combined therapy in chronic migraine Laura Marino,1 Marta Lioi1, Rosario Iannacchero,2 Michele Trimboli2 | 1Department of Neurology, Magna Graecia University, Catanzaro; 2Institute of Neurology, AOU Renato Dulbecco, Catanzaro, Italy
243 -
PO-35 | Treatment of chronic and episodic migraine with atogepant improves quality of life in patients with comorbid multiple sclerosis: the experience of the Headache Center at Spaziani Hospital, Frosinone Laura Borrello; Fabiana Marinelli; Maria Lorena Marziale; Ilaria Avallone; Fulvio Ferrante; Roberto De Simone | Neurology Unit, Headache Center, Multiple Sclerosis Center, UOC Pharmacy, Spaziani Hospital, Frosinone (FR), Italy
137 -
PO-75 | Network meta-analysis comparing efficacy and safety outcomes of atogepant, rimegepant, and galcanezumab in patients with episodic migraine after including CHALLENGE-MIG Trial Jessica Ailani,1 Pranav Gandhi,2 Anjana Lalla,2 Peter McAllister,3 Tanya Bilchik,4 Stephanie Nahas,5 David Rowe,6 Cristiano Piron,6 Kari Kelton,6 Raffaello Masselli*, Rashmi Halker Singh7 | 1MedStar Health, Washington DC, USA; 2AbbVie, North Chicago, IL, USA; 3New England Institute for Neurology and Headache, Stamford, CT USA; 4Department of Neurology, Yale School of Medicine, New Haven, CT, USA; 5Department of Neurology, Thomas Jefferson University, Philadelphia, PA USA; 6Medical Decision Modeling Inc., Indianapolis, IN, USA; 7Mayo Clinic, Phoenix, AZ, USA *Abbvie Srl, Rome, Italy. This individual has been added to this publication author by-line, with the permission of the original authors, for the express purpose of conducting the presentation at a local congress or in a local language. He did not contribute to the content of the publication.
281
1 - 16 of 16 items